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L-DNase IIibitor), the precursor of the pro-apoptotic molecule L-DNase II, belongs to the
ovalbumin subgroup of serpins. Several serpins can inhibit apoptosis: the viral serpin Crm A inhibits Fas or
TNFα-induced apoptosis, and overexpression of PAI-2 or PI-9 protects cells from TNFα or granzyme B
induced apoptosis. We have previously shown that LEI overexpression protects cells from etoposide-induced
apoptosis. The molecular reason of this anti-apoptotic activity is now investigated. We show that, in BHK-21
and HeLa cells, LEI anti-protease activity is essential for its anti-apoptotic effect. The protease inhibited is
cathepsin D, released from the lysosome during etoposide treatment. Cathepsin D enhances caspase activity
in the cell by cleaving procaspase-8 and LEI overexpression slows down this cleavage, protecting cells from
apoptosis. This let us presume that high expression of LEI in tumor cells may reduce the efﬁciency of
etoposide as a chemotherapeutic agent.
© 2008 Elsevier B.V. All rights reserved.1. Introduction
Apoptosis is a form of cell death involved in many processes such
as embryogenesis, normal tissue turnover and tumor regression. It is
characterised by several morphological changes including membrane
blebbing, cell shrinkage, phosphatidylserine externalization and
chromatin condensation [1]. The ultimate hallmark of apoptosis is
the cleavage of genomic DNA into oligonucleosomes. Many studies
have been performed to identify the endonucleases responsible for
this process and several have been identiﬁed [2–4]. Our group has
described a pathway resulting from the activation of L-DNase II, the
LEI (Leukocyte Elastase Inhibitor) derived DNase II [5].
The activation of this DNase II (acid, cation-independent DNase)
was ﬁrst discovered in lens, during chick lens differentiation [6],II, LEI-derived DNase II; HMA,
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l rights reserved.which is an apoptosis-related cellular process [7]. The activation of
this enzyme has also been seen in other models, such as neural
apoptosis during retina development [8], corneal endothelial cell
death during graft rejection [9] or in cell culture [10–12]. Previous
studies demonstrated that caspases do not participate in L-DNase II
activation [10,13–15]; LEI/L-DNase II is then classiﬁed among the
caspase-independent pathways [4].
L-DNase II activation strongly depends on the apoptotic stimulus
received by the cell. Indeed, metabolic stress is prone to induce LEI's
transformation into L-DNase II, while genotoxic stress is not. For
instance, LEI/L-DNase II pathway is activated early during HMA-
induced apoptosis, HMA being responsible of an acidiﬁcation of the
intracellular pH [13], while other stimuli, like etoposide, are not able
to induce this transformation [16]. The L-DNase II pro-apoptotic effect
in HMA-induced apoptosis was conﬁrmed by overexpression experi-
ments [14,17]. These experiments also show that LEI protects cells
from etoposide-induced apoptosis [13]. In this paradigm LEI is not
transformed into L-DNase II and apoptosis is mediated by caspases
[18,19]. Thus, LEI/L-DNase II behaves as a two edge sword: LEI has an
anti-apoptotic activity yet L-DNase II has a pro-apoptotic activity.
LEI belongs to the ovalbumin subgroup of serpins (serine
protease inhibitor), also called Clade B. Most of these serpins can
inhibit target proteases and present diversiﬁed functions [20]. Some
regulate lysosomal proteinases (squamous cell carcinoma antigen),
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sis (plasminogen activator inhibitor 2) or bone marrow differentiation
(bomapin). Others are tumor suppressors (maspin) or are implicated
in angiogenesis (antithrombin) [21]. Moreover, several serpins can
inhibit apoptosis: the viral serpin Crm A inhibits Fas or TNFα-induced
apoptosis [22]. Likewise, overexpression of PAI-2 or PI-9 protects cells
from TNFα or granzyme B induced apoptosis [23], respectively.
According to these data it is not surprising that LEI in its native form
has anti-apoptotic properties. However, the molecular reason of this
apoptotic activity is not known. In this article we investigate the basis
of the anti-apoptotic activity of LEI in etoposide-induced apoptosis
and show that it is mediated through the inhibition of cathepsin D.
2. Materials and methods
2.1. Materials
Etoposide was obtained from Alexis Corporation; tetrazolium 3-
(4,5-dimethylthiazol-2-yl)-2,5 phenyltetrazolium bromide (MTT) and
Hexa-methylene-amiloride (HMA) were purchased from Sigma; pre-
stained molecular weight markers for electrophoresis were from
BioRad. Immobilon P was obtained from Millipore. The expression
vectors pREP10 andpZeoSV2were from Invitrogen. The vectors pcDNA-
CrmA and pEBB-XIAP were obtained from Addgene, Cambridge USA.
Anti-human caspase-8 antibodies from mouse, rabbit and goat were
fromSanta Cruz Biotechnologies, aswell as anti-lamin B, anti-VDAC and
anti-Lamp 1. Anti-cathepsin D was from Oncogene Laboratories. HRP
conjugated anti-rabbit and anti-mouse were from Vector laboratories,
HRP conjugated anti-chicken IgY was from Promega. Goat anti-rabbit
Alexa 546 and goat anti-mouse Alexa 488 were fromMolecular Probes
(Invitrogen). FITC conjugated anti-chicken IgYwas fromPromega. Anti-
LEI from rabbit and from hen were prepared in our laboratory.
Mitotracker Red CM-H2XRos was from Molecular Probes (Invitrogen).
Antipain, AEBSF, pepstatin A, z-YVAD, z-DEVD, z-VVEID, z-IETD and z-
VAD were from Alexis Biochemicals, aprotinin and chymostatin were
from LKT Laboratories, Inc, and TPCK and TLCK were from Sigma
Chemical CO. Pepstatin A-Bodipy was from Invitrogen.
2.2. Cell culture
Baby Hamster Kidney (BHK-21–21) cells were grown as amonolayer
in Dulbecco's modiﬁed Eagle's medium (D-MEM-Glutamax, Invitrogen)
supplemented with 10% fetal calf serum (FCS), 200 U/ml penicillin and
0.2 mg/ml streptomycin (all from GIBCO, Invitrogen). Cells were grown
at 37 °C in a humidiﬁed atmosphere containing 5% CO2.
HeLa cells were grown in D-MEM (Invitrogen) supplemented with
10% fetal calf serum (FCS), 50 mM glutamine, 200 U/ml penicillin and
0.2 mg/ml streptomycin (all from GIBCO, Invitrogen). Cells were
grown at 37 °C in a humidiﬁed atmosphere containing 5% CO2.
2.3. Cell treatment
BHK-21 or HeLa cells were seeded at a density of 15,000 cells/cm2,
maintained in culture for 2 days and then treated for 3 h with 100 μM
etoposide. Thereafter, the drug was removed and cells were maintained
in culture with fresh medium for 24 h. In experiments where protease
inhibitors were used, these were added to the cell fresh medium just
after the removal of etoposide. The concentrations used herein were
chosen as optimal from a dose-response curve previously performed.
2.4. LEI cloning in pZeo vector
The porcine LEI cDNA was subcloned from pREP10 [13] into the
XhoI/BamHI restriction sites of pZeoSV2(+) (Invitrogen). Escherichia
coli DH5α strain was transformed by electroporation and plasmid
DNA was prepared using the HiSpeed Plasmid Maxi kit (QIAgen).2.5. Site directed mutagenesis
Site directed mutagenesis was performed on a wild type LEI-
pET23d(+) (Novagen) and pREP10LEI constructions using the Quick-
Change mutagenesis kit from Stratagene and according to the
manufacturer's protocol. An alanine residue of the hinge region of
the reactive loop of LEI was changed into threonine, and the mutant
was called AP10T. Mutants were entirely sequenced.
2.6. Transient overexpression of LEI
BHK-21 cells were seeded at a density of 15,000 cells/cm2 and
cultured as described for 48 h on 25 cm2 plates. 2 h before
transfection, the culture medium was replaced by fresh medium.
The transfection medium containing 10 μg of pREP-LEI [13] wt or
AP10T, or 10 μg of pcDNA-CrmA or pEBB-XIAP and 60 μl of Lipofectin
reagent (Life Technologies, Inc.) in 0.5 ml of serum-free D-MEM was
incubated 20min at room temperature, then diluted with D-MEM to a
ﬁnal volume of 2.5 ml and added to BHK-21 cells. The transfection
process occurred at 37 °C for 4 h, then 2.5 ml of D-MEM containing
20% FCS serumwas added to the cells [13]. Control cells were prepared
by using the empty vectors or the transfection reagent only.
HeLa cells were seeded at a density of 45,000 cells/cm2 and cultured
for 24hon25 cm2plates. The transfectionmediumcontaining5 μgof the
plasmid vectors and 10 μl of jetPEI (Polyplus transfection) in 0.5 ml of
150 mM NaCl was incubated 20 min at room temperature, then diluted
into 3ml of freshmedium and added to HeLa cells. Cells were incubated
2hat 37 °C, then3.5mlof freshmediumwere addedand the transfection
process occurred for 24 h at 37 °C. Control cells were prepared by using
the pZeo empty vector or the transfection reagent only.
2.7. Recombinant LEI, AP10T and calmodulin production
E. coli BL21(DE3)pLysS strain (Promega) were transformed with a
pET 23d(+) plasmid (Novagen) coding for pig LEI with a 6xHis tag [5].
Cultures were grown in L-Broth containing 34 μg/ml chloramphenicol
and 50 μg/ml ampicillin. Expression was induced when DO600nm was
0.6 by the addition of 1 mM isopropyl-1-thio-β-D-galactopyranoside
(IPTG, Boeringher, Manheim) for 2.5 h. Proteins were then extracted
with a binding buffer (5 mM imidazole, 0.5 mM NaCl, 20 mM Tris–HCl
pH 7.9). The proteinwas bound to a Ni-NTA column (Sigma) and eluted
in 1 M imidazole, 0.5 M NaCl, 20 mM Tris–HCl pH 7.9. Protein
concentration was measured with the Bradford assay using bovine
serum albumin as standard (Pierce Protein Plus Assay kit; Perbio
Sciences, Brebières, France). Same protocol was used for AP10T LEI
mutant and calmodulin constructions.
2.8. LEI–caspase interaction
Different LEI concentrations were incubated with 2 active units of
several caspases (1 to 10) in 50 mM Hepes pH 7.2, 50 mM NaCl, 5%
glycerol, 0.1% Chaps and 10mMdithiothreitol (DTT), in the presence of
the appropriate pNA labeled substrate. Caspase activity was followed
using a BioRad microplate reader at 405 nm. In every case, variable
concentrations of recombinant LEI were added in order to achieve
molar concentrations of LEI ranging from 0.25 to 2 folds the molar
concentration of the studied caspase.
2.9. Pull down
Recombinant proteins (wild type LEI, AP10T LEI mutant and
calmodulin) were produced in BL21pLysS E. coli strain and loaded into
a His-select cartridge (Sigma) according to the manufacturer's
protocol. HeLa cells were grown at conﬂuence for 3 days in 75 cm2
ﬂasks before lysis in RIPA buffer (50 mM Tris, pH 7.2, 150 mM NaCl, 1%
Triton X-100, 1% DOC, 1% SDS, 2 mM PMSF, 1 μg/ml leupeptin, 5 μg/ml
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material was quantiﬁed with Bradford assay (BioRad), 25 μg of each
one was resolved by SDS-PAGE and immunoblotted for caspase-8
(50 μg of proteins were loaded in this case), cathepsin D (Sigma) and
LEI. Calmodulin was used as a negative control and crude extract of
HeLa cells (25 μg) as a positive control.
2.10. MTT reduction assay
BHK-21 andHeLa cells were seeded and treated as describe above, in
24-wells plate. TheMTTwasdiluted inPBS at a concentration of 1mg/ml.
At the end of cell treatment, culture mediumwas removed and 250 μl of
MTTwas added to eachwell. Theplatewas kept in a CO2 incubator for 1h
at 37 °C. Cells were then lysedwith 250 μl of isopropanol. MTT reduction
in each sample was subsequently assessed by measuring absorption at
570 nm versus 630 nm using a microplate reader (BioRad) [13].The
survival rate was expressed as the percentage of the untreated cells.
2.11. Immunocytochemistry
BHK-21 and HeLa cells were seeded in wells of Lab-Tek lips and
treated or not with etoposide. After incubation and treatment, cells were
washed twicewithPBSCa2+–Mg2+,ﬁxed in4%paraformaldehyde (15min
at room temperature) and thenwashed twicewith PBS (when anti-Lamp
1wasused cellsweremethanolﬁxed). The cellswerepermeabilizedwith
Triton 0.03% (15min). Non-speciﬁc protein binding siteswere blocked by
incubation in a blocking buffer containing 1% skimmed milk in PBS (1 h,
room temperature). Cells were then incubated with LEI, caspase-8,
cathepsin D or Lamp 1 antibodies (dilutions are 1/200,1/50,1/300,1/300
respectively) in 0.1% skimmed milk in PBS. This was followed by ﬁve
washes with 0.1% skimmedmilk in PBS and incubation for 1 hwith an 1/
100 dilution of the appropriate secondary antibody. Cells were ﬁnally
washed with PBS, incubated for 5 min with 4-6 di-amindino-2-phenyl
indoledichloride (DAPI) and washed twice with PBS. Immunoreactivity
was visualized using ﬂuorescence microscopy with an Olympus micro-
scope or with a PCM200, Nikon confocal epiﬂuorescence microscope.
Conjugated secondaryantibodies aloneandcells stainedwith isotypically
matched control immunoglobulin were run in parallel as negative
controls. Mitochondria were labeled by incubation 15 min at 37 °C in
fresh complete mediumwith Mitotracker before PBS wash and ﬁxation.
2.12. Reticulocyte lysate-coupled transcription-translation
TnTcoupled reticulocyte lysate systemwas purchased from Promega
(Madison, WI). One microgram of plasmid DNA was incubated in
conditionsdescribedby themanufacturerwith Sp6RNApolymerase and
inpresence of 743,105Bq (20mCi) of [35S]methionine (at 1000 Ci/mmol)
for 1 h at 30 °C. A control reaction containing non-coding DNA was
performed and no protein bands appeared.
2.13. LEI inhibitory complex
5 μl of the reticulocyte lysate reaction was incubated with 2 μg of
elastase or different caspases in 50 mM Hepes pH 7.2, 50 mM NaCl, 5%
glycerol, 0.1% Chaps and 10 mM dithiothreitol (DTT). Aliquots of the
reactions were taken at different times, an equal volume of Laemmli
loading buffer was added to stop the reaction and loaded on 12% SDS-
PAGE (BioRad). After themigration gelswere treatedwith 30%methanol/
10% acetic acid for 15 min, En3hancer (DuPont de Nemour) for 15 min,
washed 3 times with water and treated 5–10 min with ethanol.
Subsequently they were dried out and exposed for autoradiography.
2.14. Western blot analysis
Total BHK-21 and HeLa cell extracts were obtained by collecting the
cells at the end of the treatment period and lysed in Laemmli buffer.Extracted proteins were separated by SDS-PAGE, immobilized on
nitrocellulose membrane (Millipore, Billerica, MA, USA) and blotted
with: anti-caspase-8, anti-LEI, anti-cathepsin D, anti-lamin B or anti-
actin at 1/1000 dilution. The secondary antibodies were used in a 1/
10,000 dilution. The amount of total protein extracts analysed was
25 μg/lane unless otherwise indicated.
2.15. Mitochondrial fractionation
Mitochondrial fractions were prepared using the Mitochondrial
Isolation Kit for tissue from Pierce, according to the manufacturer's
instructions.
2.16. Microsomal fractionation
Cells were trypsinized from a 75 cm2 ﬂask, washed twice with
saline phosphate by centrifugation for 5 min at 1500 rpm and
extracted by potterization in 2 ml of 10 mM Tris–HCl, 1 M EDTA,
250 mM Sucrose pH 7.4. The extract was centrifuged once 10 min at
600 g to discard intact cells and debris. The supernatant of this
centrifugation was then centrifuged for 1 h at 100,000 g (4 °C) using a
TLC 100 Beckman centrifuge. The supernatant of this centrifugation
was considered as the cytosolic fraction, the pellet was recovered in
200 μl of the same buffer and called the microsomal fraction.
2.17. Caspase-8 cleavage by cathepsin D
Cytoplasmic fractions fromHeLa cells were prepared by cell lysis in
a hypotonic solution (3 mM MgCl2), followed by centrifugation for
15 min at 8000 g, 4 °C. 50 μg of the supernatant proteins was then
incubated for different periods with 2 IU of active cathepsin D (Sigma
chemical co) in a buffer containing 0.2 M glycine pH 3.1 at 45 °C. The
reaction was stopped by transferring the tubes in an ice-cold water
bath. The digested fractions were then loaded on a 12% SDS-PAGE,
transferred on a nitrocellulosemembrane and developedwith an anti-
caspase-8, as previously described.
2.18. GST-caspase-8–LEI interaction
Recombinants LEI and full length GST-procaspase-8 were produce
in E. coli as described before. A glutathione column was used in the
place of Ni column to purify procaspase-8. PBS containing 0.05%
Tween, 2 mM EDTA, 10 mM DTT was used as extraction and exclusion
buffer; elution was done with 50 mM Tris pH 8.0, 5 mM glutathione.
200ngof procaspase-8, GSTor LEIwasﬁxed in a 96-well ELISAplate,
by incubation for 1 h at 37 °C in a Vollers buffer (0.05 M carbonate pH
9.6). Backgroundwas evaluated by a lanewithout protein. Non-speciﬁc
binding sites were saturatedwith BSA 1% in Vollers for 1 h at 37 °C. The
wells were then washed twice with PBS-Tween (0.05% Tween in PBS)
and loadedwith increasing concentrations of LEI diluted in PBS-Tween,
0.1% BSA. Elisa plate was incubated for 1 h at room temperature, rinsed
three timeswith PBS-Tween, incubated 1hwith 1/1000 anti-LEI in PBS-
Tween-BSA, rinsed as before and incubated 1 h againwith peroxydase-
conjugated-anti-rabbit IgG. Peroxydase activity was developed with
OPDA (o-phenylenediamine, from Sigma) diluted in a phosphate-
sodium citrate buffer pH 5.0, and this reaction was stopped by the
addition of sulphuric acid 4 N before reading at 405 nmwith a BioRad
microplate reader. Peroxydase activity of the antibody is converted into
absolute amounts of LEI by referring to the calibration curve of LEI.
2.19. Cathepsin D inhibition by LEI
2 units of active Cathepsin D (Sigma) were incubated in a 0.1 M
glycine buffer pH 3.1 containing 12.5 mg/ml bovine haemoglobin
(Sigma), in the presence or in the absence of different concentrations
of LEI. Samples of 60 μl were taken every 40 min. The reaction was
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Samples were then centrifuged in a Sigma bench top centrifuge at
15,000 rpm for 15 min at 4 °C. Ten microliters of the supernatant
containing the peptides produced by the cleavage of haemoglobin by
cathepsin D, was evaluated for protein content using the BCA method.
2.20. Statistics
Results are presented as means±s.e.m. Unless otherwise stated,
statistical signiﬁcance was assessed by Student's t-test.
3. Results
3.1. The anti-apoptotic activity of LEI is related to its anti-protease
activity
In order to verify if the anti-protease activity of LEI was involved in
cell protection after an etoposide stress, we introduced a point
mutation in the hinge region of LEI (Fig. 1A). We transformed an
alanine in position P10 of LEI into threonine (AP10T mutant). This
mutant has been shown to have a decreased anti-protease activity [24].
BHK-21 cells were transiently transfected with wild type (wt) LEI
or AP10T mutant by using lipofectin as the transfection reagent. The
presence of LEI in these cells was veriﬁed by western blot analysis, as
seen on Fig. 1B. In AP10T-LEI transfected cells there was a partial
cleavage of the expressed protein. Nevertheless, this degradation wasFig. 1. (A) AP10T point mutation. Ribbon representation of LEI. PDB ﬁle (HLE1) was obtained
version 2.7 [46]. Arrow indicates themutated alanine in P10 position, spaceﬁll displayed. (B) L
containing wild type LEI (wt LEI) or hinge region mutant (AP10T LEI), lysed, and immunob
transfected cells while AP10T mutant shows an increased cleavage (arrowheads), indicatin
BHK-21 cells. AP10T mutant of LEI was transfected into BHK-21 cells and revealed by immun
(D) Rate of survival of etoposide-treated cells expressing AP10T or wt LEI. BHK-21 (grey bar
with 100 μM etoposide for 3 h. After a recovery period of 24 h, the rate of survival was meas
lipofectin (transfection agent) treated cells, “EV” holds for cells transfected with the pREP
mutated protein expressing cells. Cells overexpressing wild type LEI are protected from et
different from the others of the same cell line, pb0.005; ⁎⁎Signiﬁcantly different from thenot deleterious for cells: cells overexpressing wild type LEI or AP10T-
LEI had the same survival rate under unstressed condition. This is
probably because the cleaved protein was mostly retained in the
cytoplasm, as seen on Fig.1C, while its pro-apoptotic effect can only be
seen when it is translocated to the nucleus [17]. The microscopy ﬁeld
shown in this ﬁgure was chosen because it presents many transfected
cells that allow the evaluation of transfected LEI cellular localisation,
the whole culture showing about 60% of the cells that clearly
overexpressing the protein. In fact, immunoﬂuorescence analysis did
not show any difference in the distribution of the mutant protein
compared to the wild type. In addition, the cleaved protein generated
from AP10T seems still functional: when an appropriate apoptotic
stimulus (Hexa-methylene-amiloride, HMA, treatment, for example)
allowing LEI transformation into L-DNase II was used, the cleaved
AP10T form could be translocated to the nucleus as an active
endonuclease. So that, HMA-induced cell death in AP10T-LEI tran-
siently transfected cells showed the same apoptosis rate than wt LEI
transfected cells, indicating that this mutant retains its pro-apoptotic
activity when transformed into L-DNase II (not shown). On the
contrary, when these cells were treated with etoposide they did not
present the same survival rate than cells overexpressing an equivalent
amount of thewild typemolecule (Fig.1D). Expression of wild type LEI
enhanced BHK-21 cells survival towards etoposide but this protection
was lost in AP10T-LEI overexpressing cells. This is true for HeLa, as
well as for BHK-21 cells. These data suggested that the anti-protease
activity of LEI was essential for its anti-apoptotic activity. Note that infrom amino acid sequence using the Swiss-model server. File was analysed with RasMol
EI overexpression. BHK-21 cells were transfectedwith empty pREP vector (empty), pREP
lotted with anti-LEI after separation in a 12% SDS-PAGE. LEI was not detected in non-
g the loss of the anti-protease activity of LEI. (C) Immunoﬂuorescence of AP10T-LEI in
ocytochemistry using an anti-LEI antibody. Note the cytosolic localisation of the protein.
s) or HeLa cells (black bars) were transfected as in B and induced to die by incubation
ured using the MTT method. “NT” indicates the non-transfected cells, “Lf” indicates the
empty vector, “LEI” indicates the LEI wild type protein and “AP10T” the hinge region
oposide-induced apoptosis. This protection is lost in the AP10T mutant. ⁎Signiﬁcantly
others of the same cell line, pb0.001.
Fig. 2. (A) Effect of LEI on caspase activity. 2 units of human recombinant caspases or elastase were incubated with the appropriate buffer and pNA-derived substrate (at a saturation
concentration) in the presence or absence (x=0) of different concentrations of LEI. The reaction was followed for 2 h and the initial speed of the reaction was calculated for each
concentration of LEI by using the linear part of the curve. In every case a ﬁxed molecular ratio between caspases (or elastase for the positive control) and LEI was kept, explaining the
differences in the amount of LEI used for every enzyme. Only caspase-9 seems to slightly decrease its activity. Note that axes are different for each enzyme and activity variations in
the other caspases are irrelevant. (B) Analysis of the caspase-9–LEI interaction. Serpins formwith the inhibited protease a covalent inhibitory complex that lasts several minutes. The
complex LEI-Elastase can be seen 5 min after the beginning of the reaction. To show this complex, recombinant 35S LEI produced by in vitro transcription-translation was incubated
for different periods with an equimolar amount of recombinant elastase (left panel). The reaction is stopped by the addition of an equal volume of Laemmli sample buffer. The
obtained sample is separated by PAGE. Labeled LEI is identiﬁed by autoradiography. On the left panel, arrowhead indicates the position of the LEI-elastase complex seen at 20min but
not present at the beginning of the reaction. This complex has an apparent molecular weight of 64 kDa (elastase 24+LEI 42). Right panel shows the same experiment done with
caspase-9. In this case different times were tested. Open arrowhead shows the position expected for the complex. No inhibitory complex is seen at any of the tested incubation times.
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consisting in 3 h of etoposide exposure followed by 24 h in
etoposide-free medium before evaluating cell survival. This was
used because we formerly showed that replacing the medium by a
fresh one induced cell division and increased cell death [25].
3.2. Effect of LEI on caspase activity in etoposide-treated cells
Several studies have demonstrated that caspases are activatedduring
apoptosis induced by etoposide [18,19]. Therefore we investigated if LEI
coulddirectly interact and inhibit caspases activity. Recombinant LEIwas
produced in E. coli and the inhibiting property of LEI was evaluated
against caspases (Fig. 2A). As shown in this ﬁgure, only caspase-9 seemsFig. 3. (A) Co-immunoprecipitation of LEI and caspase-8. Left panel shows the result of an im
an anti-LEI (rabbit polyclonal) developed with anti-caspase-8 (mouse monoclonal Alexis 80
were done in parallel by immunoprecipitating the extract with a preimmune antibody. Righ
precipitating antibody and anti-LEI (hen polyclonal) as primary antibody for western blot. Neg
of anti-caspase-8. (B) Pull down of caspase-8. Recombinant-His-tagged wild type LEI and calm
column to exclude non-speciﬁc interactions, total HeLa cells extracts were loaded on the colu
in 12% SDS-PAGE, transferred and developed with anti-caspase-8 (mouse monoclonal Alex
(C) GST-procaspase-8 and LEI interaction. Procaspase-8 and GST were ﬁxed to a 96-well ELI
amount of bound LEI wasmeasured by immuno-quantiﬁcation, using an LEI standard curve to
curvewhile GST has a non-speciﬁc binding level. The amount of LEI bound is 2.5 pmol, corresp
rate of 1 molecule of LEI per molecule of procaspase-8. (D) Caspase-8 in etoposide-induced
apoptosis was induced with etoposide. The protein concentration of total cellular extracts
developed using an anti-caspase-8 (mouse monoclonal Alexis 804–242). LEI overexpressionto be slightly inhibited, although the rate and pattern of inhibitionwere
very different from those obtained with elastase. No signiﬁcant change
was seen on the other caspases except for caspase-1 where a slight
increase of activity according to LEI concentration was seen.
Serpins inhibit their cognate protease by a tight binding mechanism
[26] leading to a covalent complex between both molecules. Hence, if
caspase-9 is inhibited by LEI, a covalent complex between them should
be detected. We produced 35S labeled LEI by in vitro transcription-
translation andexposed it to oneactive unitof caspase-9. Thepresenceof
the covalent LEI-caspase-9 complex was analysed after gel electrophor-
esis. Fig. 2B shows no complex formation between LEI and caspase-9
even for long incubationperiods, indicating that there is no tight binding
inhibition. Elastase has been used as a positive control (Fig. 2B). In thismunoprecipitation of a HeLa cell extract (induced or not in apoptosis by etoposide) with
4–242). The immunoprecipitated band corresponds to procaspase-8. Negative controls
t panel shows the same experiment using anti-caspase-8 (goat polyclonal sc-5263) as
ative controls were also performed in parallel by using non-immune goat serum instead
odulin were produced in E. coli and ﬁxed on a Ni2+ column. After extensive wash of the
mns, washed and then elutedwith 1M imidazole. The obtained proteins were separated
is 804–242). ce stands for cellular extract and represents 50 μg of HeLa cells extract.
SA plate. Different concentrations of LEI were allowed to bind to the ﬁxed proteins. The
translate absorbance into amount of LEI. Procaspase-8 shows a rapid saturation binding
onding to themolar amount of procaspase-8 loaded on thewells. This suggests a binding
HeLa cells. HeLa cells were transfected with pREP (empty vector) or with pREP-LEI and
was measured and 50 μg of each sample was loaded on a 12% SDS-PAGE, blotted and
inhibits caspase-8 activation. This effect is lost in AP10T-LEI expressing cells.
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caspase-9 itself because there is no known serpin inhibiting caspase-9.
Taken together these results show that LEI is unable to inhibit caspases
activities.
3.3. Caspase-8 and -6 are very important in etoposide-induced apoptosis
As direct caspase inhibition is not involved in LEI protection against
etoposide-induced apoptosis, we assessed then the question of which
protease could mediate LEI's effect. We thus treated etoposide-
induced cells with several protease inhibitors to see which one
could mimic LEI's effect. Only Z-VEID and Z-IETD, caspase-8 and -6
inhibitors respectively, increased signiﬁcantly cell survival while,
surprisingly, all the other tested inhibitors did not (Supplementary Fig.
1A). It is worth noting that the pan-caspase inhibitor Z-VAD was not
protective. Moreover, we have noted a strong induction of cell death
by this inhibitor itself, probably explaining this result. In addition,
overexpression of known inhibitors of caspases like CrmA or XIAP did
inhibit apoptosis (Supplementary Fig. 1B), conﬁrming that this cell
death is mediated by caspases.Fig. 4. (A) Cathepsin D is released from the lysosome in etoposide-induced apoptosis. HeLa an
microsomal (μ) and cytoplasmic (cy) fractions were separated, transferred to a nitrocellul
fractions obtained from HeLa cells are shown. (B) Cathepsin D cleaves procaspase-8 in vitro
cathepsin D. Caspase-8 activated form increases with time, as procaspase-8 decreases. (C) LEI
of haemoglobin cleaved, in the presence (0.5 pM x; 2.5 pM□ and 5 pM●) or absence (■) of L
LEI.As LEI is not able to form a complex with activated caspases we
looked for a partner that could mediate this inhibition. We ﬁrst
investigated this issue by immunoprecipitating (IP) LEI and caspase-6
and -8. As shown on Fig. 3A, LEI immunoprecipitated procaspase-8 in
etoposide-induced cells but also in healthy cells. No interaction with
active caspase-8 was seen. On the contrary, no co-immunoprecipita-
tion of caspase-6 and LEI could be seen (data not shown).
In order to verify the LEI–procaspase-8 interaction, pull down
experiments using a crude extract of HeLa cells were performed.
Recombinant His-tagged LEI was prepared from bacteria, puriﬁed and
ﬁxed on Ni2+ columns. A crude extract of HeLa cells was then loaded
on the columns and the retained material was analysed with an anti-
caspase-8. As seen on Fig. 3B, LEI pulled down a fraction of the loaded
procaspase-8. Lane ce has been charged with the crude extract loaded
on the Ni2+ columns. A naive protein, His-tagged calmodulin, was used
as a negative control.
It is worth noting that neither IP experiments, nor pull down
experiments revealed active caspase-8 but always procaspase-8. To
investigate if LEI can directly bind procaspase-8 we puriﬁed
recombinant LEI and recombinant procaspase-8 and we analyzed ind BHK-21 cells were induced to die by etoposide exposure. Cells were then collected and
ose membrane after gel separation and developed with the indicated antibodies. The
. A crude extract of HeLa cells was digested in a time-dependent manner with 2 IU of
inhibits cathepsin D activity. Activity of cathepsin D (5 pM) wasmeasured as the amount
EI. ◊ represents the experiment without cathepsin D. Cathepsin D activity is inhibited by
Fig. 5. (A) Co-immunoprecipitation of cathepsin D with caspase-8 and LEI. Left panel shows the result of an immunoprecipitation of a HeLa cells extract (apoptosis-induced or not by
etoposide) with an anti-LEI revealed with an anti-cathepsin D. The immunoprecipitated protein corresponds to active cathepsin D. Negative controls were done in parallel by
immunoprecipitating the extract with a preimmune antibody (not shown). Right panel shows the same experiment using an anti-caspase-8 as the precipitating antibody and an anti-
cathepsin D as the primary antibody for western blot. Negative controls were also performed in parallel with a non-immune goat serum instead of anti-caspase-8 (not shown). Note
that in this case only pro-cathepsin D was pulled down, and in both healthy and apoptotic cells. (B) Co-immunoprecipitation of LEI with anti-caspase-8 and anti-cathepsin D.
Immunoprecipitation of untreated HeLa cells extract with an anti-caspase-8, anti-cathepsin D or anti-LEI. Negative controls were done in parallel by immunoprecipitating the extract
with a preimmune serum for LEI and non-immune sera for the other antibodies (not shown). Western blot of the resulting protein fractions was developed with anti-LEI. (C) Pull
down of cathepsin D. Recombinant His-tagged wild type LEI, AP10T-LEI and calmodulin were produced in E. coli and puriﬁed on a Ni2+ column. Total HeLa cells extract was loaded on
the columns, washed and then eluted with 1 M imidazole. The obtained proteins were separated in a 12% SDS-PAGE, transferred to nitrocellulose and developed with anti-cathepsin
D. AP10T-LEI pulls down aweak amount of cathepsin D. On the contrary, wild type LEI pulls down huge amounts of cathepsin D, mostly linked to LEI as a covalent complex or in a free
active state. ce stands for cellular extract and calmodulin (cal) was used as a negative control. (D) inhibition of etoposide-induced apoptosis by a cathepsin D inhibitor. BHK-21 and
HeLa cells were treated with 100 μM etoposide for 3 h, then the culture medium was renewed in the absence or in the presence of 100 nM pepstatin A-Bodipy. C: control cells, E:
etoposide; P: pepstatin A-Bodipy, E+P: etoposide+pepstatin A-Bodipy. ⁎Chi-square test, pb0.05.
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negative control (Fig. 3C). To do this, 200 ng of procaspase-8 or GST
was ﬁxed to the bottom of a 96-well plate. This corresponded to
2.5 pmol of procaspase-8 and 6.6 pmol of GST. Different amounts of
LEI were then allowed to bind to the ﬁxed proteins. The bound amount
of LEI was then determined using an anti-LEI revealed by a
peroxydase-linked secondary antibody and referring the product of
the obtained optical density to a reference curvewith known amounts
of LEI runned in parallel. This experiment showed a saturation type of
curve between LEI and procaspase-8, while GST–LEI interaction
showed a linear, non-speciﬁc type of binding at the tested concentra-
tions of LEI. This indicated that LEI directly interacts with procaspase-
8. As this is the inactive form of the enzyme we speculated that LEI
could inhibit the activation of caspase-8. In order to verify this point,
we transfected wild type LEI into HeLa cells and induced apoptosis
with etoposide. Fig. 3D shows levels of activated caspase-8 in LEIoverexpressing and control cells (transfected with the empty vector).
LEI overexpression importantly decreased caspase-8 activation. More-
over, if the same experiment was performed in AP10T transfected cells
the level of active caspase-8 was recovered, indicating that a protease,
inhibited by LEI was activating caspase-8.
3.4. LEI–caspase-8: the cathepsin D connection
In these experiments we observed that procaspase-8 and LEI
interact, and that in etoposide-induced apoptosis LEI inhibits the
activation of caspase-8. However, as LEI was not able to inhibit directly
caspase-8 activity (Fig. 2A), its presence should not impair auto-
caspase-8 activation. We presumed then that another protease might
be involved in this activation.
Cathepsin D is the major intracellular aspartic protease, released
from lysosomes early after etoposide treatment [27]. The release of
Fig. 6. (A) Cellular location of cathepsin D, caspase-8 and LEI in HeLa cells. Cellular localisations of cathepsin D, caspase-8 and LEI were investigated by immunostaining. Upper panel
shows caspase-8 (green) and MitoTracker (red), indicating a mitochondrial location of caspase-8. Middle panel shows the lysosomal location of cathepsin D (red), using a Lysosome-
Associated Membrane Protein (LAMP 1, green). Bottom panel shows LEI (green) and MitoTracker (red). A fraction of LEI colocalises with mitochondria. Same results were obtained
with BHK-21 cells (data not shown). (B) Cellular location of caspase-8, LEI and cathepsin D in healthy and etoposide-treated cells. In healthy cells cathepsin D (red) is located in
lysosomes (LAMP 1, green), but it is released in etoposide-treated cells (upper panel); LEI (green) and caspase-8 (green) do not seem to change location but are joined by cathepsin D
in etoposide-treated cells (middle and bottom panels).
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and western blot of cathepsin D (Fig. 4A). Some reports also suggested
that caspase-8 may be activated by cathepsin D [28]. We therefore
veriﬁed this activation by incubating HeLa cytoplasmic extract with
puriﬁed cathepsin D (Fig. 4B). As seen on this ﬁgure, cathepsin D is
able to activate caspase-8. Thereafter, we looked for cathepsin D
inhibition by LEI. Cathepsin D was incubated alone or with increasing
concentrations of puriﬁed LEI. As seen on Fig. 4C, LEI inhibits cathepsin
D activity in vitro.
We then sought to determine the interaction between these three
proteins (LEI, procaspase-8 and cathepsin D) by immunoprecipitation
experiments. As seen on Fig. 5A, immunoprecipitation of LEI co-
precipitates active cathepsin D (34 kDa) mainly in etoposide-treated
HeLa cells suggesting that there could be a protein complex including
procaspase-8, LEI and cathepsin D. In accordance with this hypothesis,
LEI was co-immunoprecipitated by anti-caspase-8 and anti-cathepsin
D (Fig. 5B). Moreover, pull down experiments of a crude cell extract
performed as before indicated that cathepsin D interacted with wild
type LEI (Fig. 5C, lane wt). This interactionwas decreased if the AP10T-LEI mutant was used (lane AP10T) and no interaction was seen with a
naive protein (calmodulin) (lane cal).
Taken together these results suggested that LEI might regulate
cathepsin D activity to protect cells. As the effect of LEI was quite
important, the inhibition of cathepsin D should be very protective for
the cells. However, the use of pepstatin A, the inhibitor of cathepsin D,
did not protect the cells (Supplementary Fig. 1A). In order to verify this
point we use a cell permeable derivative of pepstatin A, pepstatin A-
Bodipy, which is ﬂuorescent and thus allowed veriﬁcation of its
penetration into the cell. By using this inhibitor we obtained a
signiﬁcant protection of the cells (Fig. 5D), indicating that the
inhibition of cathepsin D mimics the effect of LEI overexpression.
3.5. LEI, cathepsin D and caspase-8 in healthy and apoptotic cells
The results showed above indicated that LEI, procaspase-8 and
cathepsin D could interact. However, these molecules had a precise
subcellular localisation that might impair their interaction. This point
was not analysed by our previous experiments. According to the
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sub-membrane and mitochondrial fractions [29], cathepsin D is a
lysosomal enzyme and LEI is a cytoplasmic protein [5]. Immunoloca-
lisation of these proteins in BHK-21 and HeLa cells showed a pattern
consistent with the expected localisations for cathepsin D and
procaspase-8 (Fig. 6A) but also suggested a mitochondrial localisation
of a fraction of LEI (Fig. 6A, bottom panel). In order to validate this
mitochondrial localisation of LEI, we prepared intact mitochondria
from HeLa cells and we investigated the presence of LEI by western
blot. A fraction of LEI and a fraction of procaspase-8 are linked to
mitochondria (Supplementary Fig. 2). Purity of the different fractions
was veriﬁed with anti-actin and anti-lamin B and the mitochondrial
protein VDAC.
Fig. 6B shows the localisation of LEI, cathepsin D and caspase-8 in
healthy HeLa cells and in etoposide-treated cells, as seen by confocal
microscopy. Same results were obtained for BHK-21 cells (not shown).
According to these data a fraction of procaspase-8 and LEI colocalised
in the mitochondria, while pro-cathepsin D was located in the
lysosomes in healthy cells (left panel). After etoposide treatment,
cathepsin D was released from lysosomes and part of it colocalised
with caspase-8 and LEI (Fig. 6B, right panel and Fig. 5A). Anti-caspase-
8 showed a more diffuse localisation, while LEI did not change
subcellular compartment.
4. Discussion
The most extensive evidence linking non-caspase proteases with
apoptosis originates from studies of calpains [30], cathepsins [31] and
granzymes [32,33]. These proteases often cooperate with caspases,
but they can also trigger apoptosis by themselves [31].
In etoposide-induced apoptosis, various studies have demon-
strated the importance of caspases [18,34,35] and recent studies have
highlighted the importance of caspase-8 [36], a result that was
conﬁrmed in our apoptosis paradigm. In this mechanism, caspase-8
activation is independent of any death receptor pathway. As a matter
of fact, it has been demonstrated that procaspase-8 can be triggered
by a genotoxic stress or directly by other proteases, like granzyme B or
HIV-1 protease [37]. In etoposide-induced cell death, caspase-8
activation occurs without DISC formation [38], interchain caspase-8
cleavage being sufﬁcient.
Recent works indicate that an important fraction of procaspase-8 is
associated with mitochondria [36], a result conﬁrmed in HeLa andFig. 7.Mechanism of LEI protection from etoposide-induced apoptosis. During etoposide-ind
caspase-8. This will amplify the pre-existing activation loop of caspase-mediated apoptosis. H
inhibited by LEI, thus slowing down the activation of caspase-8 and protecting cells from aBHK-21 cells studied in this work. Interestingly, this localisation is
shared by LEI. This enzyme, which bears an anti-protease activity, was
known to have a cytoplasmic localisation [5]. However, its precise
intracellular localisation has never been studied before. Here we show
that a fraction of LEI is also associated with mitochondria. LEI and
procaspase-8 are able to interact in mitochondria and confocal
experiments support this co-localisation (data not shown). However,
we have never immunoprecipitated active caspase-8 with LEI, but
always procaspase-8, suggesting that LEI probably interacts with the
prodomain of this enzyme. However, LEI overexpression inhibits the
activation of caspase-8, thus we hypothesize the existence of a third
molecule involved in the process of caspase-8 activation. The results
presented in this paper indicate that this enzyme could be a lysosomal
enzyme, cathepsin D.
Besides caspases, lysosomal proteases are among the ﬁrst
proteases to be associated with programmed cell death [39]. The
key-factor in determining the type of cell death (apoptosis versus
necrosis) mediated by lysosomal enzymes, cathepsins, seems to be the
magnitude of lysosomal permeabilization and thus, the amount of
proteolytic enzymes released into the cytosol. Moreover, cathepsins
can be translocated from the lysosomal lumen to the cytosol in
response to a wide variety of death stimuli [40]. Among them,
cathepsins B, D and L are released to the cytosol after etoposide- or
staurosporine-treatment [27]. In some models, cathepsins have been
suggested to act independently of caspases [41], whereas in other
models apoptosis was suggested to be caspase-dependent [42,43].
Cathepsins may then trigger mitochondrial membrane permeabiliza-
tion followed by caspases-mediated apoptosis [44]. In this work we
investigated the participation of cathepsin D and we show that this
enzyme is released in its active form from lysosomes and that it is
inhibited by LEI. Moreover, recent work indicates that cathepsin D can
activate caspase-8 both in vitro and in vivo [28], a result also
conﬁrmed in this study. Immunoprecipitation studies verify the
interaction of LEI, caspase-8 and cathepsin D. It is worth noting that
the interaction of LEI with active cathepsin D is found mostly during
etoposide-induced apoptosis, while anti-caspase-8 co-precipitates
only a small amount of pro-cathepsin D and this does not change in
apoptotic or healthy cells (Fig. 5A). This suggests that interaction of
caspase-8 or procaspase-8 with active cathepsin D is very quick, and
corresponds to a substrate interaction. Also, anti-caspase-8 brings
down mostly pro-cathepsin D, probably because after cleavage of
procaspase-8 the remaining afﬁnity of active cathepsin D for theuced apoptosis, cathepsin D is released from lysosomes and increases the activation of
owever, in cells overexpressing LEI, active cathepsin D released from lysosomes will be
poptosis.
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these IP experiments were done from total extracts and that pro-
cathepsin D seems not to signiﬁcantly accumulate in the cytoplasm
during etoposide-induced apoptosis (Fig. 4A).
An important feature is that AP10T-LEI mutant has almost
completely lost its capacity to bind cathepsin D (Fig. 5C). The presence
of this mutation slows down the insertion of the reactive site loop in
the main beta sheet leading to a decrease in the stability of the
covalent complex [24], so that AP10T-LEI mutant has been shown to
have a decreased anti-protease activity [17]. This led us to the
conclusion that the anti-protease activity of LEI is essential for its
binding to cathepsin D and that LEI probably inhibits cathepsin D in a
serpin-like manner. LEI is known to be a serine protease inhibitor, its
already known substrates are elastase, proteinase A, cathepsin G and
AP24. Our results show that it is also able to inhibit cathepsin D which
is an aspartate protease. The point of cleavage on LEI has not been
established; however, sequence analysis shows a string of amino acids
downstream of P'4 that could be a good candidate for this cleavage.
The results presented here indicate that following etoposide
treatment, cathepsin D will be released into the cytoplasm and cleave
procaspase-8 inducing a burst of caspase-8 activity. This pathway of
activation of caspase-8 is regulated by LEI and could be slowed down
by LEI overexpression (Fig. 7).
It is interesting to note that although LEI is a ubiquitous protein,
levels of expression are very variable in different cells and tissues
(unpublished results). So that, tissues expressing higher levels of LEI
may use this mechanism of control of caspases activity in addition
with others previously described, like IAPs [45]. Furthermore, as LEI is
the precursor of an endonuclease, L-DNase II [5], and its transforma-
tion induces a caspase-independent apoptosis [10,13,15], the level of
expression of LEI together with the nature of the cellular injury may
modulate cell survival.
The results presented here reveal the ﬁrst characterised interaction
between the LEI/L-DNase II system and other pathways of cell death,
so that it increases our knowledge of the cellular network controlling
this process. Further experiments are needed in order to see if the
anti-apoptotic properties of LEI are seenwhen apoptosis is induced by
other stimuli activating caspase-8, such as death receptor activation,
or if it is only relevant in the present paradigm.
In any case, the presence of important amounts of LEI in some
tumors may reduce the efﬁciency of the treatment by etoposide, a
commonly used chemotherapeutic agent.
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